{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:01:54Z","timestamp":1792674114074,"version":"4.5.0"},"reference-count":37,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,12,12]]},"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>Rituximab (375\u2009mg\/m<jats:sup>2<\/jats:sup>) achieved remission of the first episode and six relapses of nephrotic syndrome (NS) in a young male patient with podocyte phospholipase A<jats:sub>2<\/jats:sub> receptor (PLA<jats:sub>2<\/jats:sub>R)-related membranous nephropathy (MN) refractory to steroids and cyclosporine. Between-treatments interval averaged 17.4\u00b14.2 months. The seventh infusion was complicated by delayed serum-sickness, which resolved with steroids. On subsequent relapse, the fully human anti-CD20 monoclonal antibody ofatumumab (300\u2009mg) achieved remission of the NS, without significant side effects. Circulating CD19<jats:sup>+<\/jats:sup> B cells were depleted, proteinuria decreased from 10.9 to 1.3\u2009g\/day, and serum albumin, immunoglobulin levels and glomerular filtration rate normalised. Twenty-eight\u2009months later, despite transient anti-PLA<jats:sub>2<\/jats:sub>R depletion, ofatumumab (100\u2009mg) failed to induce remission of the eighth relapse. Remission was safely achieved 5\u2009months later with repeated ofatumumab infusion (300\u2009mg). This treatment (\u20ac723) was less expensive than rituximab (\u20ac1801). Ofatumumab could be a safe and cost\/effective rescue therapy for patients with MN sensitised against rituximab.<\/jats:p>","DOI":"10.1136\/bcr-2019-232896","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T04:15:27Z","timestamp":1579839327000},"page":"e232896","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":43,"title":["Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness"],"prefix":"10.1136","volume":"13","author":[{"given":"Manuel Alfredo","family":"Podest\u00e0","sequence":"first","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy"},{"name":"Unit of Nephrology and Dialysis, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ruggiero","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy"},{"name":"Division of Nephrology, Department of Pediatric Subspecialties, Ospedale Pediatrico Bambino Ges\u00f9 IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy"},{"name":"Unit of Nephrology and Dialysis, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,1,23]]},"reference":[{"key":"2025082700280586000_13.1.e232896.1","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2018-135729"},{"key":"2025082700280586000_13.1.e232896.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.92"},{"key":"2025082700280586000_13.1.e232896.3","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015111262"},{"key":"2025082700280586000_13.1.e232896.4","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.9"},{"key":"2025082700280586000_13.1.e232896.5","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016091022"},{"key":"2025082700280586000_13.1.e232896.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61566-9"},{"key":"2025082700280586000_13.1.e232896.7","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07570712"},{"key":"2025082700280586000_13.1.e232896.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810457"},{"key":"2025082700280586000_13.1.e232896.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409354"},{"key":"2025082700280586000_13.1.e232896.10","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010111125"},{"key":"2025082700280586000_13.1.e232896.11","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014070640"},{"key":"2025082700280586000_13.1.e232896.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11042-7"},{"key":"2025082700280586000_13.1.e232896.13","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012020181"},{"key":"2025082700280586000_13.1.e232896.14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002628"},{"key":"2025082700280586000_13.1.e232896.15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"2025082700280586000_13.1.e232896.16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJMe1906666","article-title":"A first step toward a new approach to treating membranous nephropathy","volume":"381","author":"Ruggenenti","year":"2019","journal-title":"N Engl J Med"},{"key":"2025082700280586000_13.1.e232896.17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1681\/ASN.V62257","article-title":"Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate","volume":"6","author":"Gaspari","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"2025082700280586000_13.1.e232896.18","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01180307"},{"key":"2025082700280586000_13.1.e232896.19","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/j.1756-185X.2011.01645.x","article-title":"Serum sickness and severe angioedema following rituximab therapy in RA","volume":"15","author":"Kumar","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"2025082700280586000_13.1.e232896.20","first-page":"107","article-title":"Reactions to rituximab in an outpatient infusion center: a 5-year review","volume":"5","author":"Levin","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2025082700280586000_13.1.e232896.21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaci.2018.02.018","article-title":"Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes","volume":"142","author":"Isabwe","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2025082700280586000_13.1.e232896.22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.anai.2016.05.013","article-title":"Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist","volume":"117","author":"Khan","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025082700280586000_13.1.e232896.23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.semarthrit.2015.06.014","article-title":"Rituximab-induced serum sickness: a systematic review","volume":"45","author":"Karmacharya","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2025082700280586000_13.1.e232896.24","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjh.15177","article-title":"Rituximab-induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of anti-rituximab antibodies","volume":"184","author":"Vendramin","year":"2019","journal-title":"Br J Haematol"},{"key":"2025082700280586000_13.1.e232896.25","first-page":"771","article-title":"Repeated rituximab-induced serum sickness with anaphylaxis","volume":"57","author":"Isoda","year":"2016","journal-title":"Rinsho Ketsueki"},{"key":"2025082700280586000_13.1.e232896.26","doi-asserted-by":"crossref","unstructured":"Podest\u00e0 MA , Gennarini A , Portalupi V , et al . Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab. Nephron 2019:1\u20136.doi:10.1159\/000501858","DOI":"10.1159\/000501858"},{"key":"2025082700280586000_13.1.e232896.27","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016040449"},{"key":"2025082700280586000_13.1.e232896.28","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11791018"},{"key":"2025082700280586000_13.1.e232896.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348656"},{"key":"2025082700280586000_13.1.e232896.30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151522"},{"key":"2025082700280586000_13.1.e232896.31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMc1714146","article-title":"Ofatumumab for TTP in a patient with anaphylaxis associated with rituximab","volume":"378","author":"Crowley","year":"2018","journal-title":"N Engl J Med"},{"key":"2025082700280586000_13.1.e232896.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1308488"},{"key":"2025082700280586000_13.1.e232896.33","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00467-017-3866-2","article-title":"Single infusion of low-dose ofatumumab in a child with complicated nephrotic syndrome with anti-rituximab antibodies","volume":"33","author":"Fujinaga","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"2025082700280586000_13.1.e232896.34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00467-016-3498-y","article-title":"Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab","volume":"32","author":"Vivarelli","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"2025082700280586000_13.1.e232896.35","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-210208","article-title":"Low-Dose ofatumumab for rituximab-resistant nephrotic syndrome","volume":"2015","author":"Bonanni","year":"2015","journal-title":"BMJ Case Rep"},{"key":"2025082700280586000_13.1.e232896.36","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology"},{"key":"2025082700280586000_13.1.e232896.37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01340","article-title":"Imaging mass cytometry and single-cell genomics reveal differential depletion and repletion of B-cell populations following ofatumumab treatment in cynomolgus monkeys","volume":"10","author":"Theil","year":"2019","journal-title":"Front Immunol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-232896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:28:14Z","timestamp":1756279694000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-232896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,23]]},"published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1136\/bcr-2019-232896"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-232896","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}